Literature DB >> 32037934

A retrospective study on prephase therapy prior to definitive multiagent chemotherapy in aggressive lymphomas.

Luis Malpica1, Bolanle Mufuka2, Jonathan Galeotti3, Xianming Tan4, Natalie Grover1, Stephen M Clark5, Anne Beaven1, Hyman Muss1, Christopher Dittus1.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32037934      PMCID： PMC7271260          DOI： 10.1080/10428194.2020.1725505

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  10 in total

1.  Prednisone therapy of acute lymphatic leukemia in children.

Authors:  C B HYMAN; P STURGEON
Journal:  Cancer       Date:  1956 Sep-Oct       Impact factor: 6.860

2.  Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

Authors:  Michael Pfreundschuh; Joerg Schubert; Marita Ziepert; Rudolf Schmits; Martin Mohren; Eva Lengfelder; Marcel Reiser; Christina Nickenig; Michael Clemens; Norma Peter; Carsten Bokemeyer; Hartmut Eimermacher; Anthony Ho; Martin Hoffmann; Roland Mertelsmann; Lorenz Trümper; Leopold Balleisen; Ruediger Liersch; Bernd Metzner; Frank Hartmann; Bertram Glass; Viola Poeschel; Norbert Schmitz; Christian Ruebe; Alfred C Feller; Markus Loeffler
Journal:  Lancet Oncol       Date:  2008-01-15       Impact factor: 41.316

3.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

Authors:  Michael Pfreundschuh; Lorenz Trümper; Anders Osterborg; Ruth Pettengell; Marek Trneny; Kevin Imrie; David Ma; Devinder Gill; Jan Walewski; Pier-Luigi Zinzani; Rolf Stahel; Stein Kvaloy; Ofer Shpilberg; Ulrich Jaeger; Mads Hansen; Tuula Lehtinen; Armando López-Guillermo; Claudia Corrado; Adriana Scheliga; Noel Milpied; Myriam Mendila; Michelle Rashford; Evelyn Kuhnt; Markus Loeffler
Journal:  Lancet Oncol       Date:  2006-05       Impact factor: 41.316

4.  Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies.

Authors:  Yanli Li; Zandra Klippel; Xiaolong Shih; Maureen Reiner; Hong Wang; John H Page
Journal:  Support Care Cancer       Date:  2016-06-08       Impact factor: 3.603

5.  Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group.

Authors:  Michael Pfreundschuh; Viola Poeschel; Samira Zeynalova; Mathias Hänel; Gerhard Held; Norbert Schmitz; Andreas Viardot; Martin H Dreyling; Michael Hallek; Carsten Mueller; Martin H J Wiesen; Mathias Witzens-Harig; Lorenz Truemper; Ulrich Keller; Tanja Rixecker; Carsten Zwick; Niels Murawski
Journal:  J Clin Oncol       Date:  2014-11-17       Impact factor: 44.544

6.  Role of prephase treatment prior to definitive chemotherapy in patients with diffuse large B-cell lymphoma.

Authors:  K C Lakshmaiah; Vikas Asati; Govind Babu K; Lokanath D; Linu Abraham Jacob; Suresh Babu M C; Lokesh K N; Rajeev L K; Rudresh A H; Smitha Saldanha; Deepak Koppaka; Rajesh Patidar; Premalata C S
Journal:  Eur J Haematol       Date:  2018-04-26       Impact factor: 2.997

7.  How I treat elderly patients with diffuse large B-cell lymphoma.

Authors:  Michael Pfreundschuh
Journal:  Blood       Date:  2010-08-30       Impact factor: 22.113

8.  Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphoma.

Authors:  Yingying Cui; Xin Li; Zhenchang Sun; Changsen Leng; Ken Young; Xiaolong Wu; Lei Zhang; Xiaorui Fu; Ling Li; Xudong Zhang; Yu Chang; Feifei Nan; Zhaoming Li; Jiaqin Yan; Zhiyuan Zhou; Mingzhi Zhang; Wencai Li; Guannan Wang; Dandan Zhang
Journal:  Leuk Lymphoma       Date:  2015-03-11

9.  Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

Authors:  Michael Pfreundschuh; Lorenz Trümper; Marita Kloess; Rudolf Schmits; Alfred C Feller; Christian Rübe; Christian Rudolph; Marcel Reiser; Dieter K Hossfeld; Hartmut Eimermacher; Dirk Hasenclever; Norbert Schmitz; Markus Loeffler
Journal:  Blood       Date:  2004-03-11       Impact factor: 22.113

10.  Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy.

Authors:  Jordina Rovira; Alexandra Valera; Lluis Colomo; Xavier Setoain; Sonia Rodríguez; Alejandra Martínez-Trillos; Eva Giné; Ivan Dlouhy; Laura Magnano; Anna Gaya; Daniel Martínez; Antonio Martínez; Elías Campo; Armando López-Guillermo
Journal:  Ann Hematol       Date:  2014-12-14       Impact factor: 3.673
  10 in total
  1 in total

1.  HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis.

Authors:  Juan Pablo Alderuccio; Adam J Olszewski; Andrew M Evens; Graham P Collins; Alexey V Danilov; Mark Bower; Deepa Jagadeesh; Catherine Zhu; Amy Sperling; Seo-Hyun Kim; Ryan Vaca; Catherine Wei; Suchitra Sundaram; Nishitha Reddy; Alessia Dalla Pria; Christopher D'Angelo; Umar Farooq; David A Bond; Stephanie Berg; Michael C Churnetski; Amandeep Godara; Nadia Khan; Yun Kyong Choi; Shireen Kassam; Maryam Yazdy; Emma Rabinovich; Frank A Post; Gaurav Varma; Reem Karmali; Madelyn Burkart; Peter Martin; Albert Ren; Ayushi Chauhan; Catherine Diefenbach; Allandria Straker-Edwards; Andreas Klein; Kristie A Blum; Kirsten Marie Boughan; Agrima Mian; Bradley M Haverkos; Victor M Orellana-Noia; Vaishalee P Kenkre; Adam Zayac; Seth M Maliske; Narendranath Epperla; Paolo Caimi; Scott E Smith; Manali Kamdar; Parameswaran Venugopal; Tatyana A Feldman; Daniel Rector; Stephen D Smith; Andrzej Stadnik; Craig A Portell; Yong Lin; Seema Naik; Silvia Montoto; Izidore S Lossos; Kate Cwynarski
Journal:  Blood Adv       Date:  2021-07-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.